search

Tess Donckels

Director, Health Economics and Outcomes Research

Tess Donckels headshot - black and white image of a woman with midlength dark hair smiling for her headshot

Tess Donckels oversees and supports health economics and outcomes research projects for life sciences companies.

Tess brings more than 10 years of experience conducting research in health economics, health policy, and behavioral health. Her research spans a variety of therapeutic areas and topics, including adult immunization, oncology, psychiatric health, and quality of care for vulnerable populations.

Prior to joining Inovalon, Tess worked as a consultant at Discern Health and Real Chemistry, where she managed value-based care and quality measurement research projects. Earlier in her career, she conducted behavioral neuroscience research at the Seattle Children’s Research Institute.

Tess holds a Master of Science in Public Health with a focus on healthcare economics at Johns Hopkins University and a Bachelor of Science in Neurobiology from the University of Washington.

Connect on LinkedIn
Authored Content
Placeholder
Metabolic

Continuous Glucose Monitoring With Prandial Insulin Use Among Medicare Patients With Type 2 Diabetes Mellitus and Reductions in Diabetic Ketoacidosis Events

Accepted for presentation at American Diabetes Association. Findings available upon request. Contact us for more information.

Placeholder
Respiratory

Clinical and Social Drivers of Triple Therapy Initiation Amongst Patients With COPD Exacerbations: Results from the U.S. DUALITY Disparities Study.

Accepted for presentation at American Thoracic Society International Conference. Findings available upon request. Contact us for more information.

Placeholder
Respiratory

Racial/Ethnic Disparities in COPD-Related Healthcare Resource Utilization and Expenditures following Triple Therapy Initiation: Results From the U.S. DUALITY Disparities Study

Accepted for presentation at American Thoracic Society International Conference. Findings available upon request. Contact us for more information.

Placeholder
Real-world evidence

Real-World Adherence Patterns of Latanoprostene Bunod Ophthalmic Solution 0.024% in Medicare Patients With Comorbid Dry Eye Disease

Accepted for presentation at Academy of Managed Care Pharmacy. Findings available upon request. Contact us for more information.

Placeholder
Real-world evidence

Real-World Adherence Patterns of Latanoprostene Bunod Ophthalmic Solution 0.024% in Medicare Patients With Comorbid Dry Eye Disease

Accepted for presentation at American Society of Cataract and Refractive Surgery. Findings available upon request. Contact us for more information.

Placeholder
Rare disease

Change in Fracture Rate Among Patients With Hypophosphatasia Following Initiation of Asfotase Alfa: A Retrospective U.S. Claims Database Analysis

Accepted for presentation at American Society for Bone and Mineral Research. Findings available upon request. Contact us for more information.

Share